ROBERT WOOTEN: Open Payments
NPI 1922066232 · PINE BLUFF, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,220 in 65 payments from 11 companies in 2025. Trend: 2023 $961 · 2024 $904 · 2025 $1,220
Food & beverage: $1,220
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $317 |
| Neurocrine BioSciences, Inc. | 10 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $158 |
| Otsuka America Pharmaceutical, Inc. | 8 | $156 |
| Janssen Pharmaceuticals, Inc | 8 | $150 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| Alkermes, Inc. | 3 | $58 |
| Lundbeck LLC | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, INVEGA SUSTENNA, REXULTI, ABILIFY ASIMTUFII, UZEDY, VIVITROL.
Industry payments across AR — which companies pay providers there.
